CA2185448A1 - Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux - Google Patents

Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux

Info

Publication number
CA2185448A1
CA2185448A1 CA002185448A CA2185448A CA2185448A1 CA 2185448 A1 CA2185448 A1 CA 2185448A1 CA 002185448 A CA002185448 A CA 002185448A CA 2185448 A CA2185448 A CA 2185448A CA 2185448 A1 CA2185448 A1 CA 2185448A1
Authority
CA
Canada
Prior art keywords
derivative
epithelial cell
cancer
subject
lipoxygenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002185448A
Other languages
English (en)
Inventor
James L. Mulshine
Marti Jett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2185448A1 publication Critical patent/CA2185448A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement d'un cancer dérivé des cellules épithéliales chez un sujet nécessitant ce type de traitement. Ladite méthode consiste à administrer au sujet un inhibiteur de la 5-lipoxygénase ou un dérivé de ce dernier en une dose efficace pour traiter un cancer dérivé des cellules épithéliales. L'invention se rapporte également à une méthode de prévention d'un cancer dérivé des cellules épithéliales chez un sujet nécessitant ce type de prévention, laquelle consiste à administrer à ce dernier un inhibiteur de la 5-lipoxygénase en une dose efficace pour prévenir le cancer dérivé des cellules épithéliales. Les inhibiteurs de la 5-lipoxygénase appropriés utiles dans les méthodes selon l'invention sont constitués, de préférence, de 2-(12(hydroxydodéca-5,10-dinyl)-3,5,6-triméthyl-1,4-benzoquinone et de dérivés de celui-ci; d'acide nordihydroguaïarétique et de dérivés de celui-ci; et d'acide 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-t-isopropyl-indol-2-yl]-2-2-diméthylpropanoïque et de dérivés de celui-ci. L'invention porte également sur des dérivés d'hydroxy-urée faisant office d'inhibiteurs de la 5-lipoxygénase destinés à être utilisés dans la prévention et le traitement de cancers dérivés des cellules épithéliales.
CA002185448A 1994-03-14 1995-03-14 Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux Abandoned CA2185448A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21207494A 1994-03-14 1994-03-14
US08/212,074 1994-03-14

Publications (1)

Publication Number Publication Date
CA2185448A1 true CA2185448A1 (fr) 1995-09-21

Family

ID=22789451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185448A Abandoned CA2185448A1 (fr) 1994-03-14 1995-03-14 Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux

Country Status (4)

Country Link
EP (1) EP0750496A1 (fr)
AU (1) AU698313B2 (fr)
CA (1) CA2185448A1 (fr)
WO (1) WO1995024894A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
EP1031564A1 (fr) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibiteurs de la formation du nicotinamide mononucléotide et leur utilisation dans le traitement du cancer
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2010124283A2 (fr) 2009-04-24 2010-10-28 The Jackson Laboratory Procédés et compositions liées à des tumeurs malignes hématologiques
JP6393684B2 (ja) 2012-09-07 2018-09-19 バイオエレクトロン テクノロジー コーポレイション 個体のレドックス状態の調節において使用するためのキノン誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US4554276A (en) * 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
EP0290442A4 (fr) * 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc Composes pharmacologiquement actifs et leurs melanges, compositions organiques et sels metalliques.
CA1321349C (fr) * 1986-11-21 1993-08-17 Robert Zimmerman Association therapeutique d'un piegeur de radicaux libres ou d'un inhibiteur metabolique et d'une proteine bioactive
GB9012252D0 (en) * 1990-06-01 1990-07-18 Lilly Industries Ltd Pharmaceutical compounds
GB9025514D0 (en) * 1990-11-23 1991-01-09 Wellcome Found Anti-inflammatory compounds
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol

Also Published As

Publication number Publication date
WO1995024894A3 (fr) 1995-12-21
AU2272295A (en) 1995-10-03
AU698313B2 (en) 1998-10-29
WO1995024894A2 (fr) 1995-09-21
EP0750496A1 (fr) 1997-01-02

Similar Documents

Publication Publication Date Title
US6071949A (en) Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
Seibert et al. Distribution of COX-1 and COX-2 in normal and inflamed tissues
US5925669A (en) Carrier compositions for anti-neoplastic drugs
CA2185448A1 (fr) Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux
US6207700B1 (en) Amide derivatives for antiangiogenic and/or antitumorigenic use
CA2614192C (fr) Utilisation de glycerides docosahexaenoiques pour traiter des maladies tumorales
US6541519B2 (en) Methods and compositions for treating lipoxygenase-mediated disease states
JPH09510958A (ja) 大腸ガンの化学的予防薬剤および化学的治療薬剤としての２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の使用
WO1995024894A9 (fr) Utilisation d'inhibiteurs de la lipoxygenase en tant qu'agents therapeutiques et d'intervention anticancereux
AU2001251379A1 (en) Method to inhibit lipoxygenase and cancer cell proliferation
JP2001521539A (ja) 炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのイブプロフェンチオエステル（炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのアリールプロピオン酸、アリール酢酸及びサリチル酸塩のＣｏＡチオエステル）
US7034058B2 (en) Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide
KR20110042108A (ko) 새로운 메틸렌디옥시 페놀 화합물 및 질병 치료에서 이들의 사용
EP2303280A2 (fr) Compositions et procédés pour le traitement d inflammation et de lésions hyperkératotiques
EP1148783B1 (fr) Conversion de compositions d'inhibition de cox ne constituant pas des inhibiteurs selectifs de cox 2 en derives constituant des inhibiteurs selectifs de cox 2
US6762182B1 (en) Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
Heikkila et al. Inactivation of superoxide dismutase by several thiocarbamic acid derivatives
WO2006054316A1 (fr) Procede(s) d'elaboration, de stabilisation, de composition et d'administration d'acide gamma-linolenique pour tumeurs cerebrales
AU604226B2 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
CA2582045A1 (fr) Preparation therapeutique visant a eliminer l'etape de transition vers le traitement operatoire de l'hypertrophie prostatique
JP2014505729A (ja) コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
TEICHER et al. Modulation of [cis-diaminedichloroplatinum (ii) hyperthermia] therapy by inhibitors of arachidonic-Acid metabolism
Khanapure et al. Perspectives and clinical significance of the biochemical and molecular pharmacology of eicosanoids
Serhan et al. Aspirin Switches Biosynthetic Circuits Triggering Novel Eicosanoids during Cell-Cell Interactions that Are Potent Inhibitors of Neutrophil Migration and Tumor Cell Proliferation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead